Document is current

Article History

Received: 22 August 2021

Revised: 23 November 2021

Accepted: 24 December 2021

First Online: 18 March 2022

Declarations

:

: The scientific guarantor of this publication is Laure Fournier, MD PhD.

: The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

: Armelle Arnoux, PhD, has significant statistical expertise.She works in the university of Paris, AP-HP, Hôpital européen Georges Pompidou, Department of Biostatistics, Informatics and Clinical Research Unit, INSERM CIC1418-EC Clinical Epidemiology team, Paris, France.

: Written informed consent was waived by the Institutional Review Board.

: Institutional Review Board approval was obtained, which waived the need for written informed consent. Indeed, in our institutions, the patient gives a global written consent to reuse his/her data for research and education, on condition that an IRB reviews the protocol and its ethical compliance to French law.The IRB approval has been submitted with the manuscript.

: Previously to this study, we had developed our diagnostic algorithm in a training population from a data challenge, and you will find enclosed the pdf of the paper referencing the population (Lassau et al, Diagn Interv Imaging 2020), which was one among three data challenges. One of our validation population has been previously published in part, and you will also find the pdf (Auclin et al, Genitourin Cancer 2017). In this previous study, the authors used a semi-automated method to calculate skeletal muscle index, and its purpose was to determine whether sarcopenia was predictive of prognosis and toxicity for metastatic renal cell cancer patients under everolimus. We included 44 of the 124 patients from the initial study, because we needed to have access to the original CT images of patients.

: • retrospective• observational• performed at one institution